YOLFTbeta
Decoy Therapeutics Inc.

Decoy Therapeutics Inc.

DCOY · NASDAQ · Healthcare / Biotechnology

0.9752USD-0.08 (-7.56%)

Price History

Full chart

Market Stats

Previous Close1.06
Open1.02
Day Range0.91 – 1.02
52-Week Range2.18 – 55.92
Volume103.67K
Market Cap2.04M
P/E (TTM)0.03
Forward P/E0.00
EPS94.59
Dividend Yield0.00%
Beta0.56
50-Day Avg3.66
200-Day Avg6.52

About

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Frederick E. Pierce II
  • Employees11
  • Headquarters2450 Holcombe Blvd, Houston, TX, United States, 77021, USA
  • Websitehttps://decoytx.com

Leadership

  • Mr. Frederick E. Pierce IICEO & Director · b. 1962
  • Mr. Mark J. Rosenblum CPAExecutive VP of Finance & CFO · b. 1953
  • Dr. Barbara Hibner Ph.D.Chief Scientific Officer · b. 1962
  • Mr. Peter K. Marschel M.B.A., M.S.Chief Business Officer · b. 1975

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--1.01M1.27M838.14K3.47M5.23M1.84M0000
Growth (%)---+26.11%-34.24%+313.42%+51.03%-64.84%-100.00%---
Cost of Revenue12.00K49.88K662.75K506.53K430.75K--19.18K6.68K10.05K4.42K8.52M
Gross Profit-12.00K-49.88K347.92K767.97K407.39K3.47M5.23M1.82M-6.68K-10.05K-4.42K-8.52M
Gross Margin--34.42%60.26%48.61%100.00%100.00%98.96%----
Operating Expense8.02M29.16M40.23M35.49M22.48M11.73M13.02M14.63M31.83M12.88M5.73M4.10M
Operating Income-8.03M-29.21M-39.89M-34.73M-22.07M-8.27M-7.79M-12.81M-31.84M-12.89M-5.73M-12.61M
Operating Margin---3946.54%-2724.65%-2633.71%-238.53%-148.78%-696.27%----
EBITDA-8.00M-29.09M-39.61M-34.40M-21.85M-8.14M-7.59M-12.75M-22.97M-12.53M-5.57M-12.51M
EBITDA Margin---3919.11%-2699.18%-2606.49%-234.80%-145.09%-692.80%----
Net Income-8.01M-29.14M-39.49M-34.43M-21.92M-6.94M-7.35M-12.77M-31.61M-12.54M-5.58M-12.52M
Net Income Margin---3907.65%-2701.74%-2615.57%-200.18%-140.49%-693.84%----
R&D4.00M12.75M20.38M16.99M11.91M4.02M6.91M8.55M15.84M7.17M770.03K368.17K
R&D as % of Total Revenue--2016.32%1333.07%1420.80%115.99%132.11%464.54%----
Interest Expense------3.05K-----
Interest Expense % of Total Revenue------0.06%-----

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets35.61M95.07M63.21M34.99M10.39M13.89M24.93M40.83M14.65M6.59M3.02M11.06M
Total Liabilities42.15M2.88M3.90M5.89M1.11M3.31M2.77M2.11M4.27M1.30M1.51M5.17M
Total Equity-6.54M92.19M59.32M29.11M9.28M10.58M22.16M38.72M10.38M5.29M1.51M5.89M
Cash33.85M66.69M22.42M19.19M9.83M3.74M11.12M29.21M12.11M5.90M2.43M10.71M
Total Debt-----502.33K477.03K--289.64K221.87K-
Net Debt-33.85M-66.69M-22.42M-19.19M-9.83M-3.24M-10.64M-29.21M-12.11M-5.61M-2.21M-10.71M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.93M-20.75M-32.05M-27.72M-23.60M-11.58M-10.31M-10.20M-17.60M-12.85M-4.53M-4.83M
Investing Cash Flow-76.14K-27.27M-12.24M24.49M14.12M5.61M-2.60K--1.50M--764.74K
Financing Cash Flow40.99M80.84M22.10K2.63K118.01K3.58M17.69M28.30M1.99M6.64M1.06M12.34M
Capital Expenditure76.14K265.62K559.38K113.50K042.60K31.50M33577.00K
Free Cash Flow-7.01M-21.01M-32.61M-27.84M-23.60M-11.58M-10.31M-10.20M-19.10M-12.85M-4.53M-4.83M
Dividends Paid-----133.59K------
FCF to OCF101.10%101.28%101.74%100.41%100.00%100.00%100.03%100.00%108.52%100.00%100.00%100.00%
Dividend Paid to FCF------1.15%------

Earnings

Report DateMar 17, 2015May 6, 2015Aug 5, 2015Nov 4, 2015Mar 8, 2016May 4, 2016Aug 3, 2016Nov 2, 2016Mar 8, 2017May 3, 2017Aug 2, 2017Nov 6, 2017Mar 7, 2018May 2, 2018Aug 1, 2018Nov 5, 2018Mar 6, 2019May 1, 2019Aug 5, 2019Nov 13, 2019Mar 23, 2020May 14, 2020Aug 12, 2020Nov 11, 2020Mar 18, 2021May 12, 2021Aug 5, 2021Nov 4, 2021Mar 10, 2022May 12, 2022Aug 5, 2022Nov 10, 2022Mar 27, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 25, 2024May 13, 2024Aug 9, 2024Nov 14, 2024Mar 21, 2025May 14, 2025Aug 12, 2025Nov 14, 2025Mar 31, 2026May 8, 2026Aug 12, 2026Nov 13, 2026
EPS Estimate---------------0.42-0.21-0.11-0.19-3.50-2.75-2.75-15840.00-8640.00-3600.00-0.11-1800.00-2040.00-2340.00-0.09-3240.00-3780.00-3672.00--3600.00-1867.20-1728.00--9648.00-9648.00-9648.00-0.74-1.03-1.02-8481.60-6.48-4.08--
EPS Actual-1000000.00-532008.58-423721.69-479879.12-456765.48-544904.52-634987.14-585134.20-427808.18-441019.88-462582.44-483077.13-409573.06-413598.90-12.50-3.75-2.75-2.72-1.92-0.73-0.51-8938.80-5065.20-3600.00-0.10-2160.00-2520.00-2880.00-0.09-4680.00-3240.00-3551.47-4071.04-3211.20-2059.20-936.00-322.41-590.40-3412.80-136.80-1.01-1.03-0.45-21.7243.10-4.18-4.46-
Surprise---------------2876.19%-1685.71%-2400.00%-1331.58%45.14%73.45%81.45%43.57%41.38%0.00%11.74%-20.00%-23.53%-23.08%-5.88%-44.44%14.29%3.28%-10.80%-10.28%45.83%-93.88%64.63%98.58%-36.49%0.00%55.88%99.74%765.12%-2.45%--
Timing---------------------After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours---After-hoursAfter-hours---

Key Statistics & Ratios

Market Cap2.04M
Enterprise Value344.92K
Trailing P/E0.03
Forward P/E0.00
Price / Sales8.95
Price / Book0.47
EPS94.59
Book Value8.12
Revenue (TTM)227.63K
Gross Profit (TTM)-1.63M
EBITDA-6.07M
Profit Margin0.00%
Operating Margin-1055.84%
Return on Equity-827.77%
Return on Assets-73.35%
Shares Outstanding655.18K
Shares Float586.40K
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
9.67%
Insiders
10.44%
Retail / Other
79.89%

Top Institutional Holders

  • Tower Research Capital LLC
    1.02K0.16%
  • UBS Group AG
    5460.08%
  • Morgan Stanley - Brokerage Accounts
    10.00%
  • XTX Topco Ltd
    00.00%
  • Bank of America Corp
    00.00%
  • Danske Bank A/S.
    00.00%
  • Advisory Services Network, LLC
    00.00%
  • Warberg Asset Management LLC
    00.00%
  • Geode Capital Management, LLC
    00.00%
  • Advisor Group Holdings, Inc.
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    2.90K0.49%
  • Fidelity Series Total Market Index
    4770.08%
  • Horizon Kinetics Medical ETF
    200.00%

Stock Splits

  • Mar 9, 20261:12
  • Aug 18, 20251:15
  • Jun 17, 20241:8
  • Oct 17, 20221:25
  • Jul 22, 20191:25